Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NNMT | P40261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11926118 | 0.85 | KDM4E (0.42) | KDM4ENPC1LMNASMN1; SMN2MAPT | |
| Iodide SCHEMBL11261777 | 0.78 | NPC1 (0.40) | NPC1SMN1; SMN2MAPTACHENNMT | |
| SCHEMBL14621733 | 0.75 | KDM4E (0.42) | KDM4ENPC1LMNASMN1; SMN2MAPT | |
| SCHEMBL4381131 | 0.71 | NNMT (0.50) | SMN1; SMN2MAPTACHENNMTKMT2A | |
| Bromide SCHEMBL7178411 | 0.69 | PARP10 (0.41) | NPC1MAPTACHENNMTKMT2A | |
| Bromide SCHEMBL1645798 | 0.67 | KDM4E (0.58) | KDM4ELMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8120684 | 0.66 | KMT2A (0.54) | KDM4ENPC1LMNASMN1; SMN2MAPT | |
| Bromide SCHEMBL3883521 | 0.66 | KDM4E (0.78) | KDM4ENPC1LMNASMN1; SMN2MAPT | |
| SCHEMBL12283714 | 0.66 | HSD17B10 (0.39) | KDM4ESMN1; SMN2KMT2AALDH1A1TSHR | |
| Iodide SCHEMBL11262176 | 0.66 | ALDH1A1 (0.44) | KDM4ENPC1SMN1; SMN2MAPTACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346799-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICALS AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| EP-2484680-B1 | Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2013-06-26 | — | — | EP | disclosed |
| EP-2308874-B1 | Bridged monobactams useful as beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| EP-2484680-A1 | Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors | Basilea Pharmaceutica AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| EP-1965798-B1 | USEFUL MONOBACTAM ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-10-19 | — | — | EP | disclosed |
| EP-2308874-A1 | Useful beta-lactamase inhibitors | Basilea Pharmaceutica AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2010-03-04 | — | — | US | disclosed |
| EP-1965798-A2 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | Basilea Pharmaceutica AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007065288-A2 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | ACHE 135/4885KDM4E 1074/4885NPC1 3556/4885 |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | ACHE 135/4885KDM4E 1074/4885NPC1 3556/4885 |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | MGAM, MGAM2, B2M | ACHE 134/4885KDM4E 1140/4885NPC1 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.